Jay Patel, MD
Interventional Cardiology · Nashville, TNNPI 1659786945
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (34.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Philips North America LLC at 38.2% of the total. Reporting peaked in 2020 at $16,895 and has fallen 92.3% since, to $1,295 in 2025.
Across 151 payments — averaging $317.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$18K
- Medtronic$16K
- Abiomed$3K
- Penumbra, Inc.$2K
- Boston Scientific$2K
- Inari Medical, Inc.$2K
- plus $4K from 19 others
What the payments were for
- Speaking & faculty fees$10,34022%
- Grants$16,64135%
- Travel & lodging$5,28711%
- Food & beverage$8,82618%
- Education$6,84314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 14 | $18,336 |
| Medtronic(2 entities) | 15 | $16,252 |
| Abiomed | 15 | $2,644 |
| Penumbra, Inc. | 11 | $2,442 |
| Boston Scientific | 11 | $2,338 |
| Inari Medical, Inc. | 19 | $2,112 |
| Shockwave Medical, Inc | 7 | $695 |
| Abbott | 7 | $659 |
| Amgen | 14 | $651 |
| Johnson & Johnson | 15 | $456 |
| Thrombolex, Inc. | 1 | $405 |
| Teleflex LLC | 3 | $276 |
| Bayer | 1 | $114 |
| Novartis | 4 | $102 |
| AstraZeneca | 1 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $82 |
| Cordis US CORP. | 1 | $74 |
| Stryker | 1 | $52 |
| Pfizer | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Recor Medical Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- US Und$11,176
- MRI Equip Undiv$6,593
- Impella$2,461
- Indigo System$2,166
- FLOWTRIEVER CATHETER, S$1,299
- CT THROMBECTOMY SYSTEM KIT$1,299
- GENERAL - STRUCTURAL HEART$1,105
- SYMPLICITY G3$816
- GENERAL ATHERECTOMY$536
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$412
- Bashir Endovascular Catheter$405
- Repatha$405
- WATCHMAN Access System$322
- (6574) Coronary Other$287
- XARELTO$225
- Vascular Lithotripsy$170
- Resolute$164
- Hi-Torque Floppy guide wire$146
- TRAPLINER$130
- TURNPIKE$128
How this compares
$47,936 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $144,314 |
| XareltoRivaroxaban | 103 | $104,255 |
| Repatha SureclickEvolocumab | 72 | $60,943 |
| EntrestoSacubitril/Valsartan | 37 | $41,110 |
| JardianceEmpagliflozin | 22 | $23,781 |
| FarxigaDapagliflozin Propanediol | 23 | $22,511 |
| Praluent PenAlirocumab | 15 | $15,094 |
| Atorvastatin Calcium | 440 | $5,555 |
| Rosuvastatin Calcium | 341 | $4,172 |
| Metoprolol Succinate | 250 | $3,398 |
| Ezetimibe | 96 | $2,255 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 48 | $1,849 |
| Ranolazine ErRanolazine | 13 | $1,810 |
| Losartan Potassium | 165 | $1,735 |
| Carvedilol | 212 | $1,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $144,314126 claims |
| Johnson & JohnsonXarelto | $456 | $104,255103 claims |
| NovartisEntresto | $102 | $41,11037 claims |
| AstraZenecaFarxiga | $88 | $22,51123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Nashville
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Samuel HorrNashville$246K
- Colin BarkerNashville$217K
- Leah RajNashville$88K
- Andrew GoodmanNashville$57K
- John RiddickNashville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.